Pharmafile Logo

Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis


You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of their knees, and if they were really unlucky, on their face? This child may have disliked going to the swimming pool and particularly suffered from flare-ups during cold winter or hot summer months. They might have tried to cover up their skin with long-sleeved clothing, or hide their face to avoid being stared at.

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more…

Read the full article: http://bit.ly/2I9EbcK

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST

Understanding the Patient Journey

The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme.  Technology...